US Patent 6,965,027: Tofacitinib Citrate Crystal-Form Claims, Patent Scope, Expiration and Generic Risk

US Patent 6,965,027 protects pharmaceutical solid forms of tofacitinib citrate, the active pharmaceutical ingredient in Xeljanz and Xeljanz XR. Its claims cover a crystalline mono-citrate salt, a defined XRPD fingerprint, a melting-temperature range, an amorphous form and a citric-acid salt-formation process. The patent does not claim the underlying tofacitinib molecule as such.

The patent is therefore a formulation and solid-state patent within the broader tofacitinib estate owned by Pfizer. Its commercial importance depends on whether an abbreviated new drug application, or ANDA, uses the claimed citrate salt or reproduces the claimed crystalline form.

What drug does US Patent 6,965,027 protect?

The compound identified in the claims is tofacitinib citrate, the citrate salt of tofacitinib.

Tofacitinib is a selective Janus kinase inhibitor, with activity primarily against JAK1 and JAK3. Pfizer markets it in the United States as:

Product	Active ingredient	Dosage form	Main approved uses
Xeljanz	Tofacitinib citrate	Immediate-release tablet, oral solution	Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis
Xeljanz XR	Tofacitinib citrate	Extended-release tablet	Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis

The FDA approved Xeljanz in 2012 for rheumatoid arthritis. Later approvals expanded the label to psoriatic arthritis and ulcerative colitis. The FDA label identifies the active ingredient as tofacitinib citrate and describes the product as a kinase inhibitor administered orally (U.S. Food and Drug Administration, 2023).

What are the claims of US Patent 6,965,027?

The six claims divide into two technical categories: solid forms and preparation of the citrate salt.

Claim	Subject matter	Practical scope
1	A crystalline form of tofacitinib mono-citrate salt	Broad crystalline-form claim
2	Crystalline form with characteristic XRPD peaks at approximately 5.7, 16.1, 20.2 and 20.5 degrees 2-theta	Identifies the claimed form by four diffraction peaks
3	Crystalline form with the complete listed XRPD pattern	Narrower fingerprint claim
4	Crystalline form with an onset melting temperature of approximately 199°C to 206°C	Thermal-characterization claim
5	Amorphous form of tofacitinib mono-citrate salt	Separate amorphous-form claim
6	Process comprising reacting tofacitinib with citric acid	Salt-preparation process claim

The independent claims are claims 1, 5 and 6. Claims 2 through 4 depend on the crystalline-form subject matter and add analytical limitations.

How broad is claim 1 of US 6,965,027?

Claim 1 is materially broader than claims 2 through 4. It covers a crystalline form of the specified tofacitinib mono-citrate salt without requiring the four-peak XRPD pattern, the full XRPD pattern or the stated melting range.

The principal claim elements are:

Tofacitinib in the specified stereochemical configuration.
A mono-citrate salt.
A crystalline physical state.

A generic manufacturer could infringe claim 1 if its product contains the same crystalline tofacitinib citrate, even if the manufacturer characterizes the material using different analytical parameters. The absence of the specific XRPD peaks from a product specification would not necessarily avoid claim 1 if the material is the claimed crystalline salt.

Claim 1 is also more vulnerable to validity attacks than the narrower analytical claims because it contains fewer distinguishing limitations. Potential issues include anticipation by an earlier disclosure of crystalline tofacitinib citrate, obviousness based on routine salt and crystallization work, and enablement or written-description challenges if the claim is construed to cover crystalline forms beyond the form actually described.

What does claim 2 protect?

Claim 2 narrows the crystalline-form protection by requiring characteristic XRPD peaks at approximately:

5.7 degrees 2-theta
16.1 degrees 2-theta
20.2 degrees 2-theta
20.5 degrees 2-theta

These peaks function as an identification signature. In an infringement analysis, the relevant question would be whether the accused solid exhibits the specified peaks under substantially comparable measurement conditions.

The word “approximately” creates a measurement-tolerance issue. Powder diffraction peak positions can vary with instrument calibration, sample preparation, crystallinity, hydration state and data-processing methods. The patent specification and prosecution history would be important in determining the permissible deviation from each stated value.

What does claim 3 add to the patent scope?

Claim 3 requires the more extensive XRPD pattern listed in the claim. The pattern includes peaks from approximately 5.7 through 39.2 degrees 2-theta, including the following principal values:

Range	Listed peaks, degrees 2-theta
Low-angle region	5.7, 7.7, 8.9, 11.0, 11.5, 13.6, 13.9
Intermediate region	14.8, 15.2, 16.1, 16.6, 17.3, 18.7, 20.2, 20.5, 21.1, 21.4, 22.0, 23.0, 23.4, 24.0
Higher-angle region	25.0, 25.5, 26.2, 27.0, 27.5, 28.1, 28.7, 29.4, 30.1, 30.3, 31.1, 32.0, 32.8, 33.6, 34.4, 34.8, 35.3, 35.9, 36.5, 37.8, 38.5, 39.2

This claim is narrower than claim 2 because an accused product must satisfy the larger collection of diffraction characteristics. The claim may have greater evidentiary value in distinguishing the patented form from other polymorphs, but it also creates more opportunities for a generic manufacturer to argue that one or more required peaks is absent or materially shifted.

What does claim 4 protect?

Claim 4 protects the crystalline form based on an onset melting temperature of approximately 199°C to 206°C.

The melting range is not a substitute for chemical identity. A product would generally need to be the specified tofacitinib citrate crystalline form and exhibit the claimed thermal behavior. Differential scanning calorimetry, thermal gravimetric analysis and related methods would likely be relevant to testing.

The range may provide a secondary infringement theory where XRPD results are inconclusive. It may also create validity issues if the melting range is an inherent property of a form that was predictable from prior art or if routine crystallization methods would have produced the same material.

What does claim 5 protect?

Claim 5 independently covers an amorphous form of tofacitinib mono-citrate salt.

The claim does not require the crystalline XRPD peaks or the 199°C to 206°C melting range. It targets a non-crystalline solid-state form. The main technical question is whether the accused material is genuinely amorphous rather than crystalline, partially crystalline or a mixture.

Relevant testing may include:

XRPD showing a broad halo rather than sharp diffraction peaks;
differential scanning calorimetry;
solid-state nuclear magnetic resonance;
microscopy;
moisture and stability testing.

Amorphous materials can convert to crystalline forms during manufacture, storage or dissolution. That conversion can complicate both infringement and product-quality analysis.

What does claim 6 protect?

Claim 6 covers a process for preparing the tofacitinib mono-citrate salt by reacting tofacitinib with citric acid.

The claim is comparatively broad at the process level. It does not specify:

a solvent;
a temperature;
a crystallization sequence;
a drying condition;
a particular molar ratio;
a defined XRPD form; or
a particular commercial dosage form.

A process that uses tofacitinib and citric acid to form the mono-citrate salt could fall within claim 6, depending on claim construction and the precise process steps. A manufacturer could seek to avoid the claim by using a different salt-formation route, although the resulting product could still implicate claims 1 through 5.

Because claim 6 is a process claim, direct evidence of the manufacturing method may be difficult to obtain. In ANDA litigation, discovery, batch records, regulatory submissions and laboratory testing can become important.

What patents protect tofacitinib beyond US 6,965,027?

US 6,965,027 is one component of the tofacitinib patent estate. The broader estate includes compound, composition, method-of-treatment, formulation and regulatory-exclusivity rights.

Protection category	Typical subject matter	Relevance to generic entry
Compound patents	Tofacitinib and related pyrrolopyrimidine kinase inhibitors	Core molecule protection
Salt and solid-form patents	Tofacitinib citrate, crystalline forms and amorphous forms	Product identity and manufacturing
Method-of-use patents	Treatment of rheumatoid arthritis, psoriatic arthritis and ulcerative colitis	Patent certification and label carving
Formulation patents	Immediate-release and extended-release oral products	Xeljanz XR and dosage-form risk
Manufacturing patents	Salt formation, crystallization and purification	Process-specific infringement risk
Regulatory exclusivity	New chemical entity, pediatric or other FDA exclusivity	Timing independent of patent validity

The principal related U.S. patent publicly associated with tofacitinib is US Patent 7,598,257, which covers tofacitinib-related kinase-inhibitor compounds. The relevant patent family also includes international applications directed to pyrrolopyrimidine compounds and JAK inhibition.

Patent numbers, expiration dates and Orange Book listings should be analyzed at the product-and-strength level. A patent covering Xeljanz XR may not have the same legal relevance to an ANDA directed only to immediate-release tofacitinib tablets.

When does US Patent 6,965,027 lose exclusivity?

The patent issued on November 15, 2005. Its effective expiration date depends on:

the earliest effective nonprovisional filing date;
patent-term adjustment;
any terminal disclaimer;
patent-term extension;
pediatric exclusivity;
post-grant or litigation events.

The face expiration date should be taken from the current USPTO Patent Center record and the FDA Orange Book rather than calculated solely from the issue date. Patent expiration and FDA exclusivity are separate concepts under the Hatch-Waxman framework (35 U.S.C. §§ 154, 156; 21 U.S.C. § 355).

For commercial planning, US 6,965,027 should be treated as a late-life solid-form patent within the Xeljanz estate. Even if this patent expires, other listed patents may delay or constrain generic approval. Conversely, expiration of a compound patent does not automatically eliminate infringement risk under a surviving crystal-form, formulation or method-of-use patent.

What is the Orange Book status of tofacitinib?

FDA Orange Book status must be reviewed by reference to the specific Xeljanz or Xeljanz XR listing. Orange Book records identify patents submitted by the NDA holder and the associated expiration information. The listings can include patents covering:

the active ingredient;
drug product;
method of use; and
extended-release formulations.

US 6,965,027 is relevant because it claims the citrate salt forms used in the marketed product. An ANDA applicant must address each applicable listed patent through a Paragraph I, II, III or IV certification, or through a section viii statement for a method-of-use patent that the applicant intends to omit from labeling (FDA, 2024).

Which companies are challenging tofacitinib patents?

Generic applicants may challenge Xeljanz patents through Paragraph IV certifications. The public record for a particular challenge can include:

A notice-letter action filed by the NDA holder.
A patent-infringement complaint under 35 U.S.C. § 271(e)(2).
A settlement or license agreement.
A consent judgment.
An agreed launch date.
A dismissal after resolution.

The fact that a company files an ANDA does not establish that it can market immediately. Approval may be blocked by a 30-month stay, statutory exclusivity, a court injunction, a settlement date or other listed patents.

A robust competitive review should distinguish challenges to US 6,965,027 from challenges to the compound patent, extended-release formulation patents and method-of-use patents. A Paragraph IV challenge directed only to the crystal-form patent may not remove all barriers to launch.

How strong is the patent estate for tofacitinib citrate?

The strength of US 6,965,027 is mixed by claim type.

Claim group	Relative strength	Main reason
Claim 1	Moderate to weak against a strong prior-art record	Broad crystalline-form language
Claims 2 and 3	Stronger for technical identification	Defined XRPD characteristics
Claim 4	Moderate	Thermal range may distinguish the form but can be inherent
Claim 5	Variable	Amorphous-state proof and prior-art issues
Claim 6	Moderate	Broad process language, but manufacturing proof can be difficult

The most commercially useful claims are likely claims 1 through 4 when the marketed drug uses the claimed crystalline citrate. Claims 2 and 3 provide more precise analytical boundaries. Claim 6 may be important where the generic process follows conventional citric-acid salt formation.

Potential validity attacks include:

anticipation by an earlier disclosure of tofacitinib citrate;
obviousness of selecting citric acid as a pharmaceutically acceptable acid;
obviousness of screening and isolating a crystalline form;
lack of written description for a broad crystalline-form claim;
indefiniteness arising from “approximately” and analytical variability;
non-infringement based on a different polymorph or amorphous material.

What generic launch scenarios exist for Xeljanz?

Three launch scenarios are commercially relevant.

Authorized or licensed launch

Pfizer may license a generic company to launch on an agreed date. The agreement can preserve patent rights while permitting entry before the latest asserted patent expires.

At-risk launch

A generic company may launch after prevailing in litigation, obtaining a favorable claim construction, invalidating the asserted patent or accepting litigation risk. This can expose the company to damages if the patent is later upheld.

Post-expiration launch

The generic launches after all relevant patent and regulatory barriers expire. This is the lowest litigation-risk scenario but may occur after substantial price erosion has already been anticipated by payers and distributors.

For immediate-release tofacitinib, a generic may seek approval through an ANDA with a bioequivalence showing. Xeljanz XR presents separate formulation and release-profile issues. A generic applicant cannot assume that bioequivalence to immediate-release Xeljanz resolves extended-release patent or regulatory requirements.

Does tofacitinib face biosimilar risk?

No. Tofacitinib is a chemically synthesized small molecule, not a biologic. Biosimilar provisions under the Biologics Price Competition and Innovation Act do not apply. Competitive entry proceeds through the ANDA pathway, subject to patent certifications and bioequivalence requirements.

The relevant risks are generic substitution, formulation differentiation and method-of-use carve-outs, not biosimilar interchangeability.

What manufacturing and geographic barriers remain?

US 6,965,027 is a U.S. patent. It does not itself establish protection in Europe, Japan, Canada or other jurisdictions. International protection depends on national patent grants in the corresponding family.

Manufacturing barriers may remain even after patent expiration because a generic manufacturer must control:

stereochemical purity;
citrate stoichiometry;
polymorphic form;
water content;
particle-size distribution;
chemical stability;
conversion between amorphous and crystalline material; and
batch-to-batch XRPD consistency.

A manufacturer that uses a different solid form may avoid some claims but still need to demonstrate pharmaceutical equivalence, stability and bioequivalence to the reference product.

Key Takeaways

US 6,965,027 is a tofacitinib citrate solid-form and manufacturing patent.
Claim 1 broadly covers a crystalline form of tofacitinib mono-citrate salt.
Claims 2 and 3 rely on defined XRPD peak patterns.
Claim 4 uses a 199°C to 206°C onset melting range.
Claim 5 separately protects an amorphous form.
Claim 6 covers preparation of the citrate salt by reaction with citric acid.
The patent does not independently claim every use of tofacitinib or every tofacitinib dosage form.
Generic risk must be assessed against the entire Xeljanz patent estate, including compound, formulation and method-of-use patents.
Tofacitinib has generic, not biosimilar, competition.
Patent expiration must be verified against current USPTO and FDA records, including patent-term adjustment, patent-term extension, pediatric exclusivity and Orange Book listings.

FAQs

Can a generic avoid US 6,965,027 by using a different tofacitinib salt?

Yes, potentially. A non-citrate salt would not ordinarily satisfy the mono-citrate limitations, but it would require separate regulatory and pharmaceutical-equivalence analysis.

Does an amorphous tofacitinib citrate product infringe the crystalline claims?

An exclusively amorphous product would not ordinarily satisfy a crystalline-form limitation. It may still implicate claim 5 or claim 6, depending on the product and manufacturing process.

Can XRPD testing alone establish infringement?

XRPD can provide strong evidence for claims 2 and 3, but claim construction, testing conditions and the complete chemical identity of the material remain relevant.

Does an ANDA applicant have to use the Pfizer citrate manufacturing process?

No. An applicant may use a different process, but the resulting product must avoid applicable process and product claims and satisfy FDA quality and bioequivalence requirements.

Can Xeljanz method-of-use patents block a generic with a narrower label?

They can, depending on the patented indication, the proposed labeling and the adequacy of a section viii carve-out. A carved-out label does not eliminate product or formulation patent risk.

References

Food and Drug Administration. (2023). Xeljanz (tofacitinib) prescribing information. U.S. Department of Health and Human Services.
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
United States Patent and Trademark Office. (2005). U.S. Patent No. 6,965,027, crystalline form of 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile mono citrate salt. U.S. Department of Commerce.
United States Patent and Trademark Office. (2009). U.S. Patent No. 7,598,257, pyrrolopyrimidine compounds as protein kinase inhibitors. U.S. Department of Commerce.
United States Code. (2024). 35 U.S.C. §§ 154, 156, 271(e)(2).
United States Code. (2024). 21 U.S.C. § 355.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	037635	⤷ Start Trial
Austria	497962	⤷ Start Trial
Australia	2002348857	⤷ Start Trial
Brazil	0214761	⤷ Start Trial
Canada	2469350	⤷ Start Trial
China	1325498	⤷ Start Trial
China	1596257	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,965,027

Summary for Patent: 6,965,027